[Discussion] can we stop arguing about ATTAIN until somebody posts a number
can we stop arguing about ATTAIN until somebody posts a number. Searched first, found three threads that contradict each other, hence the post. Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely. Milligram comparisons across molecule classes are meaningless.…
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
Is that from the publication or the press release?
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.
the manufacturing story is genuinely different from the injectables
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
What analytical method was used — this is not the usual peptide assay question?
That is a phase 2 result being quoted as though the programme had reported.